6 recruiting, 2 active not recruiting, 1 not yet recruiting. 6 Phase 1, 2 Phase 3, 1 Phase 2.
By phase and status
Follow Xaluritamig: new trials by email Literature Review of Xaluritamig trials Research Report on Xaluritamig
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan
Xaluritamig - Prostate Cancer, Metastatic Castrate Resistant Prostate Cancer | Phase 2 | Not yet recruiting | 30 | 2026-10-01 | 2026-08-14 |
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Xaluritamig - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | 40 | 2026-04-28 | 2026-09-15 |
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Xaluritamig - Ewing Sarcoma | Phase 1 | Recruiting | 50 | 2026-04-08 | 2026-10-29 |
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Xaluritamig, Abiraterone acetate, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | 750 | 2025-11-28 | 2026-10-20 |
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Xaluritamig, Darolutamide, Abiraterone - Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 1 | Recruiting | 60 | 2025-10-07 | 2026-07-02 |
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Xaluritamig, Abiraterone, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Active not recruiting | 707 | 2024-12-09 | 2026-05-15 |
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Xaluritamig, GnRH Antagonist - Prostate Cancer | Phase 1 | Recruiting | 40 | 2024-11-25 | 2026-07-31 |
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
Xaluritamig - Prostate Cancer, High-risk Biochemical Recurrence | Phase 1 | Active not recruiting | 50 | 2024-09-23 | 2026-09-04 |
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
AMG 509, Abiraterone, Enzalutamide - Prostate Cancer | Phase 1 | Recruiting | 479 | 2020-03-04 | 2026-08-21 |
Conditions studied
Prostatic Neoplasms (8) · Bites and Stings (1) · Neoplasms (1) · Recurrence (1) · Sarcoma, Ewing (1)
Sponsors
Amgen (8) · Thomas Jefferson University (1)
Countries
United States (8) · Australia (7) · Germany (4) · Switzerland (4) · Japan (3) · South Korea (3) · Spain (3) · Taiwan (3) · Austria (2) · Belgium (2) · Canada (2) · France (2) · Greece (2) · Italy (2) · Netherlands (2)
Top investigators
Kevin K Zarrabi, MD, MS (1)
NIH funding
2023 (1)